CytoDyn Inc. financial data

Symbol
CYDY on OTC
Industry
Pharmaceutical Preparations
Location
1111 Main Street, Suite 660, Vancouver, WA
State of incorporation
DE
Fiscal year end
May 31
Former names
REXRAY CORP (to 11/12/2003)
Latest financial report
10-Q - Q3 2024 - Oct 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 14.1 % +59.9%
Quick Ratio 69.3 % -6.28%
Debt-to-equity -113 % -3.05%
Return On Equity 17.5 % -72.1%
Return On Assets -130 % +79.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.22B shares +31%
Common Stock, Shares, Outstanding 1.22B shares +31%
Entity Public Float 156M USD -47.2%
Common Stock, Value, Issued 1.22M USD +31%
Weighted Average Number of Shares Outstanding, Basic 1.14B shares +22.9%
Weighted Average Number of Shares Outstanding, Diluted 1.2B shares +29.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 7.24M USD +175%
General and Administrative Expense 9.71M USD -28.1%
Costs and Expenses -8.99M USD -125%
Operating Income (Loss) 8.99M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -19M USD +73%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -19M USD +73%
Earnings Per Share, Basic -0.02 USD/shares +75%
Earnings Per Share, Diluted -0.02 USD/shares +75%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 24.9M USD +1125%
Inventory, Net 0 USD
Assets, Current 27.7M USD +132%
Property, Plant and Equipment, Net 73K USD -45.5%
Operating Lease, Right-of-Use Asset 230K USD -37.2%
Intangible Assets, Net (Excluding Goodwill) 132K USD -92%
Other Assets, Noncurrent 283K USD -36.1%
Assets 28M USD +126%
Accounts Payable, Current 14.2M USD -77.4%
Employee-related Liabilities, Current 362K USD +3.73%
Liabilities, Current 69.6M USD -46.1%
Operating Lease, Liability, Noncurrent 105K USD -57.5%
Other Liabilities, Noncurrent 43.6M USD
Liabilities 113M USD -12.4%
Retained Earnings (Accumulated Deficit) -872M USD -2.23%
Stockholders' Equity Attributable to Parent -85.2M USD +27.1%
Liabilities and Equity 28M USD +126%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 5.44M USD
Net Cash Provided by (Used in) Financing Activities 9.67M USD +141%
Common Stock, Shares Authorized 1.75B shares +29.6%
Common Stock, Shares, Issued 1.22B shares +31%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 15.1M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.9M USD +191%
Interest Paid, Excluding Capitalized Interest, Operating Activities 45K USD +87.5%
Deferred Tax Assets, Valuation Allowance 129M USD +0.04%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 129M USD +0.02%
Operating Lease, Liability 247K USD -36.2%
Depreciation 5K USD -50%
Lessee, Operating Lease, Liability, to be Paid 308K USD -37.3%
Operating Lease, Liability, Current 142K USD +1.43%
Lessee, Operating Lease, Liability, to be Paid, Year Two 169K USD -8.65%
Lessee, Operating Lease, Liability, to be Paid, Year One 169K USD -8.65%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 61K USD -41.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 169K USD -8.65%
Deferred Tax Assets, Operating Loss Carryforwards 101M USD +4.73%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 208K USD +15.6%
Additional Paid in Capital 786M USD +6.86%
Amortization of Intangible Assets 700K USD -61.1%
Deferred Tax Assets, Net of Valuation Allowance 55K USD -34.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%